早老性痴呆药物空研究进展.ppt

How to accelerate AD research Contents 1 Current situation of AD Population：37 million Causes：too sophisticated Market drugs：Tarcrine，Donepezil，Rivastigmine，Galanthamine，Huperzine，Memantine Some social activities may correlate with AD，but cannot delay the progress of AD 2 What are big companies doing A big cake attracts a lot of big companies，attention，such as Pfizer，Elan，Merk，Novartis and so on BMC Medicine 2009, 7:7 Tramiprosate ALZHEMED（Neurochem Inc.） The Phase III trial did not show a beneficial effect on cognition or function，so the development program has been discontinued Vaccines and antibodies AN-1792（Elan）the first-generation amyloid vaccine，Phase II trial was discontinued owing to the development of aseptic meningoencephalitis in 6% of the patients ACC-001（Elan）prevent the induction of a toxic cellular immune response，in a Phase II clinical trial Bapineuzumab (Elan/Wyeth) ：Phase III，monoclonal antibodies Immunoglobulin IgIV：Phase III，polyclonal antibodies RAGE Inhibitor Amyloid is known to bind to receptors for advanced glycated endproducts (RAGE) on the surface of cells and at the blood-brain barrier； this binding may contribute to inflammation and neuronal death. PF：an orally bioavailable antagonist of RAGE，Phase II γ-secretase inhibitors Tarenflurbil：the enantiomer of the non-steroidal anti-inflammatory drug flurbiprofen，modulates the activity of γ-secretase，failed in Phase III Semagacestat：reduction of amyloid peptide generation in blood and cerebrospinal fluid of patients with AD treated with tolerable doses， in Phase III Tau aggregation inhibitor Rember（Methylene blue）：a widely used histology dye, has been shown to interfere with tau aggregation. Entering Phase III Microtubule stabilizer NAP (AL-108)：derived from a natural neurotrophic protein, can b